On June 29, Keymed Biosciences-B (02162.HK) rose 5.46% in regular trading, reaching HKD 70.05 per share, with turnover of HKD 119 million.

On the news front, AbbVie's previously announced plan to acquire Apogee Therapeutics for approximately USD 10.9 billion continues to validate multinational pharma's strategic conviction in long-acting atopic dermatitis assets. Apogee's core product is APG777, a long-acting IL-13 monoclonal antibody with dosing intervals extendable to 3-6 months. Keymed's CM512, an IL-13/TSLP bispecific antibody with a half-life of approximately 70 days, belongs to the same long-acting AD track and could similarly support extended dosing intervals, positioning it favorably in this revaluation cycle.

Additionally, the company has received a USD 257 million upfront payment from Gilead's acquisition of Ouro Medicines and a USD 45 million milestone payment from AstraZeneca for CMG901's Phase 3 initiation, significantly strengthening its cash position and further clarifying its global value realization pathway.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)